FDA approves Retatrutide this year?

Prediction markets put the probability at 12%: FDA approves Retatrutide this year. Currently, markets see this as unlikely (12% YES). The next phase of the obesity drug race.

What’s Happening

Eli Lilly presented full Phase 3 data for its next-generation triple-agonist obesity drug retatrutide at the American Diabetes Association Scientific Sessions in New Orleans on June 7, 2026, with results spanning two pivotal trials in treatment-naive type 2 diabetes patients and patients with obesity. The drug produced an average 28% body weight loss in clinical trials — the largest reduction ever recorded for a weight loss medication — and reduced body weight more than four times as much as placebo over a 40-week dosing period. Lilly shares rose 4% on June 8 as analysts projected the molecule would extend the company's lead in the metabolic disease market. [Reuters, Jun 8]

The question of whether the FDA approves retatrutide this year hinges on regulatory submission timing rather than clinical merit, as Lilly has not yet confirmed a 2026 Biologics License Application filing for the triple agonist. The BioSpace coverage of the ADA conference highlighted that Lilly's commercial focus in 2026 has centered on the newly approved oral GLP-1 pill Foundayo, while retatrutide remains positioned as the company's next-generation pipeline asset. FDA reform initiatives under the agency's current leadership also lack procedural clarity, with Commissioner Makary reportedly absent from several recent policy rollouts — a factor that complicates accelerated review timelines for novel metabolic compounds. [BioSpace, Jun 10]

Competitive pressure in the obesity space continues to intensify five years after Wegovy's initial FDA approval, with Novo Nordisk, Pfizer, Amgen, and Zealand Pharma all advancing rival weight loss assets through late-stage development. Whether the FDA approves retatrutide this year would meaningfully reshape that landscape, given the drug's expanding indication profile — Lilly's ADA presentations covered benefits in menopause-related weight gain, sleep apnea, and cardiometabolic comorbidities beyond the core obesity and type 2 diabetes endpoints. With GSK's $10.6 billion acquisition marking the largest traditional pharma buyout of 2026 and capital continuing to flow toward GLP-1 mechanisms, regulatory clarity on retatrutide's submission and review status remains the gating factor for any near-term approval decision before December 31, 2026. [CNBC, Jun 13]

Traded on Polymarket — $570K Volume

Polymarket prices this at 12c YES with $570K in volume. Moderate liquidity — use limit orders for positions above $1K to avoid moving the price.